Myrexis logo

Myrexis(OTC) MYRX

Market Cap$27.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-100%
5 Year-96%
1 Year-84%
1 Month+0%
$0.00
+0.00%
+0.00Today
Myrexis last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-07
Myrexis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-29
1 month+0%USD 0.002026-09-02
3 month+0%USD 0.002026-07-08
Year to date+100%USD 0.002025-12-24
1 year-84%USD 0.012025-10-07
3 year-84%USD 0.012023-10-05
5 year-96%USD 0.022021-10-08
Since inception-99.63%USD 0.212009-06-12

Myrexis Financials at a Glance

Market Cap

$27.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.62M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-4.04 (Low)

Price

$0.00

Volume

100

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Feb 7, 2025

MYRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Myrexis

Myrexis, Inc. is a financial services company focused on identifying and supporting ventures in the life sciences sector. Formerly known as Myriad Pharmaceuticals, Inc., the company rebranded in July 2010 and is headquartered in New York City.

Products and Services
  • Investment in life sciences ventures
  • Financial backing for innovative healthcare solutions
  • Strategic partnerships within the biotechnology sector
Growth Outlook
  • Strong cash position with $1.14 million in cash and short-term investments
  • Current ratio of 16.72 indicates excellent liquidity
  • Potential for growth in life sciences as healthcare demands increase
Financial Highlights
  • Recent quarterly net income of -$151,000, showing operational challenges
  • Trailing twelve months (TTM) cash flow per share of -$0.43
  • Market capitalization of approximately $27,583, indicating a small-cap status
Myrexis, Inc. operates in a niche market with a focus on life sciences, which is poised for growth as healthcare needs evolve. The company's strong liquidity position, as evidenced by a current ratio of 16.72, suggests it can meet short-term obligations effectively. However, recent financial performance indicates operational challenges, with a net income of -$151,000 in the latest quarter. Despite these challenges, the company maintains a significant cash reserve, which may provide opportunities for future investments and growth in the life sciences sector. The small market capitalization reflects its current standing in the market, but the potential for strategic partnerships and investments could enhance its value proposition for investors.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Headquarters

New York City, NY 10020, US

MYRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-25.67%

Return on Capital

-1031.04%

Return on Assets

-939.45%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$27.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

34.48M

Volume

100

Avg. Volume

4.70K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$11.99M

EBITDA

-$11.97M

Operating Cash Flow

-$12.97M

Capital Expenditure

$0.00

Free Cash Flow

-$12.97M

Cash & ST Invst.

$1.21M

Total Debt

$0.00

Myrexis Performance Analysis

Myrexis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12012-09-30N/A
Q22012-12-31N/A
Q32013-03-31N/A
Q42013-06-30N/A
Myrexis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12012-09-30-2189.4%
Q22012-12-31-38.5%
Q32013-03-3138.9%
Q42013-06-3095.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2012YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$27.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$27.60K

N/A

Employees

1

N/A

Net Income

-$151.00K

+96.6%

EBITDA

-$153.00K

+1.3%

Quarterly Fundamentals

Name
Q4 2012YOY CHG

Total Cash

$1.21M

-98.6%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-9.39%

N/A

Return on Invested Capital

-10.31%

N/A

Free Cash Flow

-$304.00K

+95.8%

Operating Cash Flow

-$304.00K

+95.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JADAJade Art Group Inc.
$0.00+0.00%
WORCWake Up Now, Inc.
$0.00-0.00%
CDSGChina Dongsheng International, Inc.
$0.00+10.48%
LTUSLotus Pharmaceuticals, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$32.29+5.33%
BKLCBny Mellon ETF Trust - Bny Mellon Us Large Cap Core Equity ETF
$49.57-0.33%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$18.69-6.78%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$149.83-5.71%

Questions About MYRX

What is the current price of Myrexis?

Myrexis is trading at $0.00 per share.

What is the 52-week range for Myrexis?

Over the past 52 weeks, Myrexis has traded between $0.00 and $0.01.

How much debt does Myrexis have?

Myrexis total debt is unavailable.

How much cash does Myrexis have on hand?

Myrexis does not have cash on hand data available.

What is Myrexis’s dividend yield?

Myrexis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.